Navigation

Empliciti vs. Xpovio

Are Empliciti and Xpovio the Same Thing?

Empliciti (elotuzumab) and Xpovio (selinexor) are indicated in combination for the treatment of patients with multiple myeloma.

Empliciti is used in combination with lenalidomide and dexamethasone in patients who have received one to three prior therapies.

Xpovio is used in combination with dexamethasone in patients who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.

Empliciti is a SLAMF7-directed immunostimulatory antibody and Xpovio is a nuclear export inhibitor

Side effects of Empliciti and Xpovio that are similar include fatigue, diarrhea, constipation, upper respiratory tract infection, decreased appetite, vomiting, weight loss, and low white blood cell count.

Side effects of Empliciti that are different from Xpovio include fever, cough, tingling or numbness in the hands and feet, sore throat, runny or stuffy nose, pneumonia, pain in the extremities, headache, and cataracts.

Side effects of Xpovio that are different from Empliciti include low blood platelets, nausea, anemia, low blood sodium, and shortness of breath.

Both Empliciti and Xpovio may interact with other drugs.

What Are Possible Side Effects of Empliciti?

Common side effects of Empliciti include:

  • fatigue,
  • diarrhea,
  • fever,
  • constipation,
  • cough,
  • tingling or numbness in the hands and feet,
  • sore throat,
  • runny or stuffy nose,
  • upper respiratory tract infection,
  • decreased appetite,
  • pneumonia,
  • pain in the extremities,
  • headache,
  • vomiting,
  • weight loss,
  • low white blood cell count (lymphocytopenia), and
  • cataracts.

Tell your doctor if you have serious side effects of Empliciti including:

What Are Possible Side Effects of Xpovio?

Common side effects of Xpovio include:

  • low blood platelets,
  • fatigue,
  • nausea,
  • anemia,
  • decreased appetite,
  • weight loss,
  • diarrhea,
  • vomiting,
  • low blood sodium,
  • low white blood cell counts,
  • constipation,
  • shortness of breath, and
  • upper respiratory tract infection

What Is Empliciti?

Empliciti (elotuzumab) for injection is a SLAMF7-directed immunostimulatory antibody indicated in combination with lenalidomide and dexamethasone for the treatment of patients with multiple myeloma who have received one to three prior therapies.

What Is Xpovio?

Xpovio (selinexor) is a nuclear export inhibitor indicated in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.

What Drugs Interact With Empliciti?

Premedicate with dexamethasone, diphenhydramine, ranitidine, and acetaminophen. Empliciti may interact with other drugs. Tell your doctor all medications and supplements you use. Empliciti is not recommended for use during pregnancy; it may harm a fetus. It is unknown if Empliciti passes into breast milk. Because of the potential for serious adverse reactions in breastfed infants, breastfeeding is not recommended.

What Drugs Interact With Xpovio?

Tell your doctor all medications and supplements you use. Xpovio is not recommended for use during pregnancy; it may harm a fetus. Females of reproductive potential are advised to use effective contraception during treatment with Xpovio and for one week after the last dose. It is unknown if Xpovio passes into breast milk. Because of the potential for serious adverse reactions in a nursing child, breastfeeding is not recommended while using Xpovio and for at least one week after the last dose.

How Should Empliciti Be Taken?

The dose of Empliciti given with lenalidomide and dexamethasone is 10 mg/kg administered intravenously every week for the first two cycles and every 2 weeks thereafter until disease progression or unacceptable toxicity.

How Should Xpovio Be Taken?

The recommended starting dose of Xpovio is 80 mg in combination with dexamethasone taken orally on days 1 and 3 of each week. Xpovio may interact with other drugs.

Disclaimer

All drug information provided on RxList.com is sourced directly from drug monographs published by the U.S. Food and Drug Administration (FDA).

Any drug information published on RxList.com regarding general drug information, drug side effects, drug usage, dosage, and more are sourced from the original drug documentation found in its FDA drug monograph.

Drug information found in the drug comparisons published on RxList.com is primarily sourced from the FDA drug information. The drug comparison information found in this article does not contain any data from clinical trials with human participants or animals performed by any of the drug manufacturers comparing the drugs.

The drug comparisons information provided does not cover every potential use, warning, drug interaction, side effect, or adverse or allergic reaction. RxList.com assumes no responsibility for any healthcare administered to a person based on the information found on this site.

As drug information can and will change at any time, RxList.com makes every effort to update its drug information. Due to the time-sensitive nature of drug information, RxList.com makes no guarantees that the information provided is the most current.

Any missing drug warnings or information does not in any way guarantee the safety, effectiveness, or the lack of adverse effects of any drug. The drug information provided is intended for reference only and should not be used as a substitute for medical advice.

If you have specific questions regarding a drug’s safety, side effects, usage, warnings, etc., you should contact your doctor or pharmacist, or refer to the individual drug monograph details found on the FDA.gov or RxList.com websites for more information.

You may also report negative side effects of prescription drugs to the FDA by visiting the FDA MedWatch website or calling 1-800-FDA-1088.